Palliative Treatment Of Bone Metastases With Samarium-153 Edtmp At Onset Of Pain (403 views)
J Bone Miner Metab (ISSN: 0914-8779), 2014 Jul; 32(4): 434-440.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 2.46, 5-year impact factor: 2.349
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84904538729&partnerID=40&md5=6d5acc50c0de3c6c85a7099c9056cf1d
Keywords: Low Degree Bone Pain, Palliation, Radionuclide Therapy, Sm-153 Edtmp, Analgesic Agent, Antineoplastic Agent, Etidronic Acid Tc 99m, Lexidronam Samarium Sm 153, Nonsteroid Antiinflammatory Agent, Zoledronic Acid, Adult, Article, Bleeding, Blood Toxicity, Bone Marrow Suppression, Bone Metastasis, Bone Scintiscanning, Breast Cancer, Cancer Chemotherapy, Cancer Hormone Therapy, Cancer Palliative Therapy, Cancer Patient, Cancer Radiotherapy, Clinical Article, Clinical Evaluation, Controlled Study, Drug Efficacy, Drug Safety, Female, Human, Infection, Lung Cancer, Multimodality Cancer Therapy, Pain Assessment, Physician, Priority Journal, Radioisotope Therapy, Risk Reduction, Treatment Duration, Treatment Outcome, Treatment Response, Visual Analog Scale, 80 And Over, Bone Neoplasms Radiotherapy, Middle Aged, Pain Radiotherapy, Palliative Care Methods, Samarium Therapeutic Use, Procedures, Very Elderly,
Affiliations:
*** IBB - CNR ***
Istituto di Ricovero e Cura Carattere Scientifico, Centro di Riferimento Oncologico di Basilicata, via P. Pio 1, 85028 Rionero in Vulture, Italy
Institute of Biostructure and Bioimages, National Council of Research, Naples, Italy
University of Texas Southwestern, Dallas, TX, United States
References:
Not available.
J Bone Miner Metab (ISSN: 0914-8779), 2014 Jul; 32(4): 434-440.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 2.46, 5-year impact factor: 2.349
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84904538729&partnerID=40&md5=6d5acc50c0de3c6c85a7099c9056cf1d
Keywords: Low Degree Bone Pain, Palliation, Radionuclide Therapy, Sm-153 Edtmp, Analgesic Agent, Antineoplastic Agent, Etidronic Acid Tc 99m, Lexidronam Samarium Sm 153, Nonsteroid Antiinflammatory Agent, Zoledronic Acid, Adult, Article, Bleeding, Blood Toxicity, Bone Marrow Suppression, Bone Metastasis, Bone Scintiscanning, Breast Cancer, Cancer Chemotherapy, Cancer Hormone Therapy, Cancer Palliative Therapy, Cancer Patient, Cancer Radiotherapy, Clinical Article, Clinical Evaluation, Controlled Study, Drug Efficacy, Drug Safety, Female, Human, Infection, Lung Cancer, Multimodality Cancer Therapy, Pain Assessment, Physician, Priority Journal, Radioisotope Therapy, Risk Reduction, Treatment Duration, Treatment Outcome, Treatment Response, Visual Analog Scale, 80 And Over, Bone Neoplasms Radiotherapy, Middle Aged, Pain Radiotherapy, Palliative Care Methods, Samarium Therapeutic Use, Procedures, Very Elderly,
Affiliations:
*** IBB - CNR ***
Istituto di Ricovero e Cura Carattere Scientifico, Centro di Riferimento Oncologico di Basilicata, via P. Pio 1, 85028 Rionero in Vulture, Italy
Institute of Biostructure and Bioimages, National Council of Research, Naples, Italy
University of Texas Southwestern, Dallas, TX, United States
References:
Not available.
Palliative Treatment Of Bone Metastases With Samarium-153 Edtmp At Onset Of Pain
We evaluated the pain response and daily discomfort in patients suffering from a borderline degree of bone pain due to breast or lung cancer bone metastases, who had undergone early palliative radionuclide treatment. The results were compared with those from patients who had received standard analgesic therapy. Twenty-one patients (65.7 ± 3 years; 17 women) with metastatic bone cancer underwent samarium-153 (Sm-153) ethylene diamine tetramethylene phosphonate (EDTMP) administration (group A) and 18 patients (64.3 ± 8 years; 16 women) continued to receive standard analgesics (group B; control group). The patients kept a daily pain diary assessing both their discomfort and the pain at specific sites by means of a visual analog scale, rating from 0 (no discomfort-no pain) to 10 (worst discomfort-pain). These diaries were reviewed weekly for 2 months and three physicians rated the pain response on a scale from -2 (considerable deterioration) to +2 (considerable improvement). Baseline characteristics were similar in both groups. The reduction of total discomfort and of bone pain in group A was significantly greater compared to group B (p < 0.0001). A significant improvement of clinical conditions was observed in group A, where the physician rate changed from -1 to 1, compared to group B in which the rate changed from -1 to 0. Sm-153 EDTMP therapy can be considered for patients with bone pain from breast and lung cancer in advance, i.e., before the establishment of severe pain syndrome. © 2013 The Japanese Society for Bone and Mineral Research and Springer.
We evaluated the pain response and daily discomfort in patients suffering from a borderline degree of bone pain due to breast or lung cancer bone metastases, who had undergone early palliative radionuclide treatment. The results were compared with those from patients who had received standard analgesic therapy. Twenty-one patients (65.7 ± 3 years; 17 women) with metastatic bone cancer underwent samarium-153 (Sm-153) ethylene diamine tetramethylene phosphonate (EDTMP) administration (group A) and 18 patients (64.3 ± 8 years; 16 women) continued to receive standard analgesics (group B; control group). The patients kept a daily pain diary assessing both their discomfort and the pain at specific sites by means of a visual analog scale, rating from 0 (no discomfort-no pain) to 10 (worst discomfort-pain). These diaries were reviewed weekly for 2 months and three physicians rated the pain response on a scale from -2 (considerable deterioration) to +2 (considerable improvement). Baseline characteristics were similar in both groups. The reduction of total discomfort and of bone pain in group A was significantly greater compared to group B (p < 0.0001). A significant improvement of clinical conditions was observed in group A, where the physician rate changed from -1 to 1, compared to group B in which the rate changed from -1 to 0. Sm-153 EDTMP therapy can be considered for patients with bone pain from breast and lung cancer in advance, i.e., before the establishment of severe pain syndrome. © 2013 The Japanese Society for Bone and Mineral Research and Springer.
Palliative Treatment Of Bone Metastases With Samarium-153 Edtmp At Onset Of Pain
| ▼ Animal Care, interventional procedures, anesthesia and analgesia of murine models in preclinical imaging |
Palliative Treatment Of Bone Metastases With Samarium-153 Edtmp At Onset Of Pain
Other filter: ([btitle,keywords] "Low Degree Bone Pain ...
Gallicchio R, Scapicchio D, Nardelli A, Pellegrino T, Prisco M, Mainenti P, Sirignano C, Pedicini P, Storto G
* Assessment of residual radioactivity by a comprehensive wireless, wearable device in thyroid cancer patients undergoing radionuclide therapy and comparison with the results of a home device: a feasibility study (47 views) (PDF 17 views)
Ieee J Transl Eng Health Med (ISSN: 2168-2372linking), 2020 Dec 2; 9: 2700306-2700306.
Impact Factor: 2.53
View Export to BibTeX Export to EndNote
Altug C, Gunes H, Nocentini A, Monti SM, Buonanno M, Supuran CT
* Synthesis of isoxazole-containing sulfonamides with potent carbonic anhydrase II and VII inhibitory properties (313 views)
Bioorg Med Chem (ISSN: 0968-0896, 1464-3391, 0968-0896linking), 2017 Feb 15; 25(4): 1456-1464.
Impact Factor: 2.881
View Export to BibTeX Export to EndNote
D'Antuono F, Nardelli A, Gallicchio R, Giacomobono S, Venetucci A, Pellegrino T, Leggiadro F, D'Errico N, Gattozzi D, Mainenti PP, Storto G
* Palliative Treatment of Bone Metastases with Sm-153 EDTMP at Pain Onset (314 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2013 Oct; 40: N/D-N/D.
Impact Factor: 5.217
View Export to BibTeX Export to EndNote
Storto G, Gallicchio R, Pellegrino T, Nardelli A, Capacchione D, Sirignano C, Pace L
* Impact of F-18-fluoride PET-CT on implementing early treatment of painful bone metastases with Sm-153 EDTMP (352 views) (PDF 12 views)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897, 0969-8051linking), 2013 May; 40(4): 518-523.
Impact Factor: 2.408
View Export to BibTeX Export to EndNote
Cirillo G, Colangelo AM, Bianco MR, Cavaliere C, Zaccaro L, Sarmientos P, Alberghina L, Papa M
* BB14, a Nerve Growth Factor (NGF)-like peptide shown to be effective in reducing reactive astrogliosis and restoring synaptic homeostasis in a rat model of peripheral nerve injury (409 views)
Biotechnology Advances (ISSN: 0734-9750), 2012 Jan; 30(1): 223-232.
Impact Factor: 9.599
View Export to BibTeX Export to EndNote
Nardelli A, Castaldi E, Ortosecco G, Speranza A, Storto G, Pace L, Salvatore M
* Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90 (562 views)
Applied Radiation And Isotopes (ISSN: 1872-9800, 0969-8043, 0969-8043linking), 2011 Jan; 69(1): 52-55.
Impact Factor: 1.172
View Export to BibTeX Export to EndNote
Storto G, Erra P, Pellegrino T, Nardelli A, Milone F, Di Giorgio E, Faggiano A, Castaldi E, Ortosecco G, Speranza A, Klain M, Colao A, Salvatore M, Pace L
* Efficacy and Toxicity of Peptide Receptor Radionuclide Therapy (PRRT) using medium-high activities of Y-90-DOTA-Octreotate (Y-90-DOTATATE) in patients with tumours expressing somatostatin receptors (SSTR) (260 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2008 Oct; 35: N/D-N/D.
Impact Factor: 4.532
View Export to BibTeX Export to EndNote
Storto G, Pellegrino T, Nardelli A, De Falco T, Castaldi E, Ortosecco G, Capasso E, Erra P, Speranza A, Klain M, Molino L, Di Nuzzo C, Pace L, Salvatore M
* Impact of PET-CT with F-18 Fluoride in Implementing Treatment of Painful Bone Metastases with Sm-153 EDTMP (288 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2008 Oct; 35: N/D-N/D.
Impact Factor: 4.532
View Export to BibTeX Export to EndNote
Di Fiore A, Pedone C, D'Ambrosio K, Scozzafava A, De Simone G, Supuran CT
* Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II 'selective' inhibitor celecoxib (327 views)
Bioorg Med Chem Lett Bioorganic And Medicinal Chemistry Letters (ISSN: 0960-894x), 2006 Jan 15; 16(2): 437-442.
Impact Factor: 2.538
View Export to BibTeX Export to EndNote
Storto G, Speranza A, Pellegrino T, Panico M, Cella L, Nardelli A, Russo AA, Klain M, Soricelli A, Pace L, Salvatore M
* Activity Threshold Determining Cumulative Aderse-Effects In Patients Undergoing Peptide Receptor Radionuclide Therapy With Y-90 Octreotate (290 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2006; 33: 338-338.
Impact Factor: 4.041
View Export to BibTeX Export to EndNote
Tauchmanova L, De Rosa G, Serio B, Fazioli F, Mainolfi C, Lombardi G, Colao A, Salvatore M, Rotoli B, Selleri C
* Avascular necrosis in long-term survivors after allogeneic or autologous stem cell transplantation: A single center experience and a review (316 views)
Cancer (ISSN: 0008-543x), 2003 May 15; 97(10): 2453-2461.
Impact Factor: 2.045
View Export to BibTeX Export to EndNote
Romano M, Giojelli A, Tamburrini O, Salvatore M
* Chemoembolization for hepatocellular carcinoma: Effect of intraarterial lidocaine in peri- and post-procedural pain and hospitalization (493 views)
Radiol Med (ISSN: 0033-8362, 1826-6983, 1826-6983electronic), 2003 Apr; 105(4): 350-355.
Impact Factor: 1.368
View Export to BibTeX Export to EndNote
* Assessment of residual radioactivity by a comprehensive wireless, wearable device in thyroid cancer patients undergoing radionuclide therapy and comparison with the results of a home device: a feasibility study (47 views) (PDF 17 views)
Ieee J Transl Eng Health Med (ISSN: 2168-2372linking), 2020 Dec 2; 9: 2700306-2700306.
Impact Factor: 2.53
View Export to BibTeX Export to EndNote
Altug C, Gunes H, Nocentini A, Monti SM, Buonanno M, Supuran CT
* Synthesis of isoxazole-containing sulfonamides with potent carbonic anhydrase II and VII inhibitory properties (313 views)
Bioorg Med Chem (ISSN: 0968-0896, 1464-3391, 0968-0896linking), 2017 Feb 15; 25(4): 1456-1464.
Impact Factor: 2.881
View Export to BibTeX Export to EndNote
D'Antuono F, Nardelli A, Gallicchio R, Giacomobono S, Venetucci A, Pellegrino T, Leggiadro F, D'Errico N, Gattozzi D, Mainenti PP, Storto G
* Palliative Treatment of Bone Metastases with Sm-153 EDTMP at Pain Onset (314 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2013 Oct; 40: N/D-N/D.
Impact Factor: 5.217
View Export to BibTeX Export to EndNote
Storto G, Gallicchio R, Pellegrino T, Nardelli A, Capacchione D, Sirignano C, Pace L
* Impact of F-18-fluoride PET-CT on implementing early treatment of painful bone metastases with Sm-153 EDTMP (352 views) (PDF 12 views)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897, 0969-8051linking), 2013 May; 40(4): 518-523.
Impact Factor: 2.408
View Export to BibTeX Export to EndNote
Cirillo G, Colangelo AM, Bianco MR, Cavaliere C, Zaccaro L, Sarmientos P, Alberghina L, Papa M
* BB14, a Nerve Growth Factor (NGF)-like peptide shown to be effective in reducing reactive astrogliosis and restoring synaptic homeostasis in a rat model of peripheral nerve injury (409 views)
Biotechnology Advances (ISSN: 0734-9750), 2012 Jan; 30(1): 223-232.
Impact Factor: 9.599
View Export to BibTeX Export to EndNote
Nardelli A, Castaldi E, Ortosecco G, Speranza A, Storto G, Pace L, Salvatore M
* Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90 (562 views)
Applied Radiation And Isotopes (ISSN: 1872-9800, 0969-8043, 0969-8043linking), 2011 Jan; 69(1): 52-55.
Impact Factor: 1.172
View Export to BibTeX Export to EndNote
Storto G, Erra P, Pellegrino T, Nardelli A, Milone F, Di Giorgio E, Faggiano A, Castaldi E, Ortosecco G, Speranza A, Klain M, Colao A, Salvatore M, Pace L
* Efficacy and Toxicity of Peptide Receptor Radionuclide Therapy (PRRT) using medium-high activities of Y-90-DOTA-Octreotate (Y-90-DOTATATE) in patients with tumours expressing somatostatin receptors (SSTR) (260 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2008 Oct; 35: N/D-N/D.
Impact Factor: 4.532
View Export to BibTeX Export to EndNote
Storto G, Pellegrino T, Nardelli A, De Falco T, Castaldi E, Ortosecco G, Capasso E, Erra P, Speranza A, Klain M, Molino L, Di Nuzzo C, Pace L, Salvatore M
* Impact of PET-CT with F-18 Fluoride in Implementing Treatment of Painful Bone Metastases with Sm-153 EDTMP (288 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2008 Oct; 35: N/D-N/D.
Impact Factor: 4.532
View Export to BibTeX Export to EndNote
Di Fiore A, Pedone C, D'Ambrosio K, Scozzafava A, De Simone G, Supuran CT
* Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II 'selective' inhibitor celecoxib (327 views)
Bioorg Med Chem Lett Bioorganic And Medicinal Chemistry Letters (ISSN: 0960-894x), 2006 Jan 15; 16(2): 437-442.
Impact Factor: 2.538
View Export to BibTeX Export to EndNote
Storto G, Speranza A, Pellegrino T, Panico M, Cella L, Nardelli A, Russo AA, Klain M, Soricelli A, Pace L, Salvatore M
* Activity Threshold Determining Cumulative Aderse-Effects In Patients Undergoing Peptide Receptor Radionuclide Therapy With Y-90 Octreotate (290 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2006; 33: 338-338.
Impact Factor: 4.041
View Export to BibTeX Export to EndNote
Tauchmanova L, De Rosa G, Serio B, Fazioli F, Mainolfi C, Lombardi G, Colao A, Salvatore M, Rotoli B, Selleri C
* Avascular necrosis in long-term survivors after allogeneic or autologous stem cell transplantation: A single center experience and a review (316 views)
Cancer (ISSN: 0008-543x), 2003 May 15; 97(10): 2453-2461.
Impact Factor: 2.045
View Export to BibTeX Export to EndNote
Romano M, Giojelli A, Tamburrini O, Salvatore M
* Chemoembolization for hepatocellular carcinoma: Effect of intraarterial lidocaine in peri- and post-procedural pain and hospitalization (493 views)
Radiol Med (ISSN: 0033-8362, 1826-6983, 1826-6983electronic), 2003 Apr; 105(4): 350-355.
Impact Factor: 1.368
View Export to BibTeX Export to EndNote
12 Records (7 excluding Abstracts).
Total impact factor: 42.863 (22.133 excluding Abstracts).
Total 5 year impact factor: 46.489 (25.325 excluding Abstracts).
Total impact factor: 42.863 (22.133 excluding Abstracts).
Total 5 year impact factor: 46.489 (25.325 excluding Abstracts).
403 views. Last view on Sunday 17 September 2023, 14:20:44
ibb.cnr.it
